tbuckley/cabot-search huggingface dataset:
Regulation of collagen production in freshly isolated cell populations from normal and cirrhotic rat liver: Effect of lactate
Authors: J Cerbón-Ambriz
Journal: Hepatology (1991)

Previous work has shown that lactic acid, and to a lesser extent pyruvic acid, is able to increase collagen synthesis significantly in liver slices of CCl4-treated rats but not normal rats. The purpose of this report is to document which cells in the cirrhotic liver are responsible for the lactate-stimulated increase in collagen synthesis. It was found that (a) incorporation of 3H-proline into protein-bound 3H-hydroxyproline is increased threefold to fourfold in hepatocytes from CCl4-treated rats as compared with normal rat hepatocytes; (b) neither the hepatocytes from normal nor those from CCl4-treated rats modify their collagen synthesizing capacity when 30 mmol/L lactic acid was added to the incubation medium; (c) nonparenchymal cells obtained from livers of CCl4-treated rats synthesize much less collagen than hepatocytes, but their synthesis is stimulated twofold by lactic acid; (d) from the different nonparenchymal cells, only fat-storing (Ito) cells increase collagen synthesis when lactic acid is present in the incubation medium. These results suggest that the increased lactic acid levels observed in patients with alcoholic hepatic cirrhosis may play an important role in the development of fibrosis by stimulating collagen production by fat-storing (Ito) cells. (HEPATOLOGY 1991;13:551–556.)
Bisphenol A and Dental Sealants: Olea's Response
Authors: Nicolas Olea
Journal: Environmental Health Perspectives (2000)

Comments on "Determination of bisphenol A and related aromatic compounds released from Bis-GMA-based composites and sealants by high performance liquid chromatography." by ulgar R, Olea-Serrano MF, Novillo-Fertrell A, Rivas A, Pazos P, Pedraza V, Navajas J-M, Olea N. Environ Health Perspect 108:21-27 (2000).
Prescribing of tetracycline to children less than 8 years old. A two-year epidemiologic study among ambulatory Tennessee medicaid recipients
Authors: W. A. Ray
Journal: JAMA (1977)

The Committee on Drugs of the American Academy of Pediatrics finds virtually no indications for administering tetracyclines to children less than 8 years old. This study analyzes tetracycline prescribing to ambulatory children less than 8 years of age in the Tennessee Medicaid program during a two-year period. Of the nearly 59,000 children in the study, 4,026 (7%) received 7,046 tetracycline prescriptions. Twenty-seven percent (527) of 1,947 participating physicians prescribed tetracycline; 26 physicians (5%) wrote 54% of the prescriptions for 45% of the children. Physicians in family practice prescribed the greatest quantity of tetracycline. Surgeons and internists prescribed more tetracycline to young children than did pediatricians. Rural location of practice was independently associated with increased tetracycline prescribing for all specialties. Recent graduates from medical school were less apt to prescribe tetracycline than were earlier graduates. (<i>JAMA</i>237:2069-2074, 1977)
Female cancer patients’ awareness and role in family-based medical decision making mode in Confucian area.
Authors: Xing Li, Yan-Fang Xing, Qu Lin, Li Wei, Min Dong, Xiao-kun Ma, Zhan-hong Chen, Jie Chen, Dan-yun Ruan, Ze-Xiao Lin, Tian-tian Wang, Dong-hao Wu, Xiang-yuan Wu
Journal: Journal of Clinical Oncology (2016)

237 Background: Medical decision making of Chinese patients was family based, especially for female cancer patients. However, few studies have systematically investigated female patients. We aimed to illustrate the determinant of female cancer patients’ role in decision making. Methods: A total of 286 adult female cancer patients were included in this study between September 1st 2013 and December 31st 2013 from 13 leading general hospitals across China. A questionnaire was given to the oncologists in charge to evaluate each patient concerning the interaction between family and cancer patients, patients’ awareness of disease and participation in medical decision making in mainland China. In this study, the family statuses of patients were ranked as superordinate (one who was the major decision maker in family), equality (one discussed important issues with family members and made decision with consensus of family members), and subordinate (those who usually don’t be involved in significant family issues). Results: Among the 286 cancer patients, only 29 (10.1%) patients made decision themselves. 221 (77.3%) patients delegated decision making to their family. The rest of 36 (12.6%) patients were involved in decision making. Patients with nonlocal insurance, which meant they traveled to the major cities for advanced medication, were inclined to let their family members make decision for them. Patients’ family status significantly determined their participation in medical decision making. Female patients as superordinate family members (4.5%), tend to play a positive role in medical decision. By contrast, patients with subordinate role in family (66.4%) persistantly play a passive role in medical decision making. Violation of medical recommendation increased according to the severity of patients’ prognosis. Cancer progression (90.6%), financial expense (65.7%) and life expectancy (94.1%) was always hidden from female patients by their families, especially for those with incurable disease. Conclusions: Medical decision making of female Chinese cancer patients was mainly family based. Female patients’ awareness of disease and participation in medical decision making was still needs improvement.
A System of Legal Medicine.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
"UNDULANT FEVER"
Authors: Charles H. Keene
Journal: JAMA (1930)

<h3>To the Editor:</h3> —I wish to express to you my appreciation of the editorial on page 1238 of the April 19 issue ofThe Journalconcerning undulant fever, particularly those parts relating to the advantages of pasteurized milk over unpasteurized. You probably know as well as I that the profession has been almost literally flooded with propaganda in behalf of certified milk. I am glad that the official mouthpiece of the profession has taken a stand on the side of safety.
Manuscripts Approved for JNCI, April 10 to May 10, 1963
Journal: JNCI Journal of the National Cancer Institute (1963)

Journal Article Manuscripts Approved for JNCI, April 10 to May 10, 1963 Get access JNCI: Journal of the National Cancer Institute, Volume 30, Issue 6, June 1963, Page 1381, https://doi.org/10.1093/jnci/30.6.1381 Published: 01 June 1963
Inhibitory effect of epigallocatechin-gallate on brain tumor cell lines in vitro
Authors: Shunichi Yokoyama, Hirofumi Hirano, Naruhito Wakimaru, Krishna Pada Sarker, Jun-Ichi Kuratsu
Journal: Neuro-Oncology (2001)

We investigated the effect of epigallocatechin-gallate (EGCG), the main constituent of green tea polyphenols, on human glioblastoma cell lines U-373 MG and U-87 MG, rat glioma cell line C6, and rat nonfunctioning pituitary adenoma cell line MtT/E.Cell viability was determined by assay with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), and the extent of apoptosis was studied by ow cytometric analysis.Apoptosis was also characterized by morphology using uorescent microscopy.The role of insulin-like growth factor-I (IGF-I) was studied by assay with MTT, immunohistochemistry, and immunoradiometric assay.After 72-h exposure, a statistically signi cant loss of viability (P = < 0.0001) was observed at concentrations of 12.5, 25, 50, and 100 µg/ml in U-373 MG cells and U-87 MG cells.EGCG at concentrations of 50 µg/ml and higher signi cantly reduced the viability of C6 cells.EGCG inhibited viability of MtT/E cells only at a concentration of 100 µg/ml.Quantitative study by ow cytometry demonstrated that lower doses of EGCG (12.5, 25, 50 µg/ml) induced apoptosis in U-373 MG, U-87 MG, and C6 cells; however, only the highest dose (100 µg/ml) induced apoptosis in MtT/E cells.Compared with other cell lines, MtT/E cells showed stronger IGF-I immunoreactivity.Neutralization of IGF-I with an antihuman IGF-I antibody reduced viability of the cell lines.It can be concluded that EGCG has an inhibitory effect on malignant brain tumors, and IGF-I may be involved in the effects of EGCG.
A phase I trial of of cixutumumab (C) (IMC-A12) and sorafenib (S) for treatment of advanced hepatocellular carcinoma (HCC).
Authors: Anthony B. El-Khoueiry, Robert O'Donnell, Philip C. Mack, Suzette Blanchard, Nathan Bahary, Yixing Jiang, John Joseph Wright, Helen X. Chen, Heinz-Josef Lenz, David R. Gandara
Journal: Journal of Clinical Oncology (2014)

4105 Background: The insulin growth factor (IGF) pathway is activated in hepatocarcinogenesis. C is a monoclonal antibody against insulin-like growth factor-1 receptor (IGF-1R). In vivo HCC models showed activated IGF signaling and antitumor effects due to C. Given the cross-talk between the IGF and VEGF pathways, the combination of C and S was chosen. Methods: This study evaluated the safety of C (2, 4 or 6 mg/kg) IV weekly with standard doses of S (400 mg po bid) in patients (pts) with HCC. Eligibility criteria included: no prior systemic therapy for HCC, Child-Pugh score of A or B7, ECOG 0 or 1, platelets > 75,000/mm3, and albumin > 2.8 g/dl. The study used a standard 3+3 design. One cycle was 28 days. Results: A total of 21 pts (17 males and 4 females) were enrolled; mean age was 63 years (43-85); 10 Asian, 4 Hispanic, 5 White, 1 Black, and 1 Native American. There were 3 dose limiting toxicities (DLTs); grade 3 hyperglycemia, grade 3 hypophosphatemia, and grade 5 peritonitis (see table). The maximum tolerated dose (MTD) was C 4 mg/Kg and S 400 mg BID. 18 of 21 (86%) pts had ≥grade 3 toxicities attributable to treatment. Grade 3 adverse events that occurred in ≥ 2 pts were: diarrhea (4; 19%), hypertension (4; 19%), thrombocytopenia (3; 14%), palmar-plantar erythrodysesthesia (2; 10%), hyperglycemia (2; 10%), and fatigue (2; 10%). There was 1 grade 4 colonic perforation and 1 grade 5 peritoneal infection in the same pt. The median number of cycles was 4 (0-19 cycles). Sixteen of the 21 pts completed 2 cycles and were evaluated for response. 13 of the 16 (81%) (95% CI: 54%-96%) achieved stable disease. The median event free survival was 3.8 months (95%CI: 1.9, 11.3). The median OS was 13.1 months (95% CI: 7.6, undefined). An increase of 0.5 in baseline natural log of hepatocyte growth factor and insulin growth factor binding protein 3 were associated with risk of death (log rank p value 0.01 and 0.03). Conclusions: The majority of adverse events in pts treated with the combination of C and S were typical of sorafenib toxicity. There was preliminary evidence of efficacy as seen in the median OS. Clinical trial information: NCT01008566. Dose level Pts treated Pts evaluable for dose escalation DLT 1 8 6 1 (gr 3 hyperglycemia) 2 (MTD) 6 5 None 3 7 5 2 (gr 3 hypophosphatemia, gr 5 peritonitis)
AUTHOR'S REPLY
Authors: D. Strachan
Journal: Thorax (1989)

Repeatability of ventilatory function measurements in a population survey of seven year old children SIR,-The impression was given by Dr David Strachan (June 1989;44:474-9) that the coefficient of variation for FEV, in seven year old children was low, possibly even lower than that for the vital capacity.We wonder whether this could be a spurious finding.In a recent survey of 120 healthy seven year
Blurred Vision
Authors: Bradford J. Shingleton, Mark W. O'Donoghue
Journal: New England Journal of Medicine (2000)

Blurred vision is the most common symptom related to the eye. It is manifested in many ways and has a wide variety of causes. Here we review for nonophthalmologists the examination techniques and diagnostic algorithms that are useful in the evaluation of blurred vision. We also describe how to determine when patients need urgent ophthalmologic consultation and treatment.The Eye ExaminationHistoryIn evaluating a patient with blurred vision, it is important to note the time of onset and how the patient first noticed the symptoms. Was the blurring of vision sudden in onset, or was it gradual? Did it . . .
MEDICAL CRITICISMS OF THE LATE WAR.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tick Paralysis—Washington, 1995
Journal: JAMA (1996)

Tick paralysis (tick toxicosis)--one of the eight most common tickborne diseases in the United States (1)--is an acute, ascending, flaccid motor paralysis that can be confused with Guillain-Barre syndrome, botulism, and myasthenia gravis. This report summarizes the results of the investigation of a case of tick paralysis in Washington.
Efficacy and safety of treatment interruption in patients with HBeAg negative chronic hepatitis B
Authors: Teresa Broquetas, Miquel Mico, Montserrat Garcia-Retortillo, Nuria Cañete Hidalgo, Marc Puigvehí, Susanna Coll, Marc Batlle, Ana Viu, Esther Garrido, Judit Romero, Juan Jose Hernandez, Xavier Bessa, Jose A. Carrión
Journal: Journal of Hepatology (2020)
Abstract P341: An Approach for Defining Cognitive Decline in Epidemiologic Studies
Authors: Sarah R Gillett, Abraham J Letter, Leslie A McClure, Virginia G Wadley, Frederick W Unverzagt, Brett M Kissela, Richard E Kennedy, Stephen P Glasser, Deborah A Levine, Mary Cushman
Journal: Circulation (2012)

Introduction: Prospective studies of cognitive decline are vital for the identification of risk factors and preventative strategies, but there is no established definition of cognitive decline in epidemiologic studies. To plan a case-cohort biomarker study, a panel of experts sought to identify 500 participants with significant cognitive decline in the REasons for Geographical and Racial Differences in Stroke (REGARDS) cohort. Methods: REGARDS is a population-based cohort of 30,239 black and white Americans enrolled from 2003-7 in their homes and followed by telephone. Global cognitive function was measured serially using the Six Item Screener (SIS), and learning, memory, and executive function using Word List Learning (WLL), Word List Recall (WLR), and Animal Fluency (AF) tests. In an initially cognitively intact cohort (SIS &gt; 4 at baseline), cognitive decline was defined as performance 1.5 SD below the age-, race-, sex-, and education-based norms on 2 of 3 cognitive domain scores (AF, WLL, WLR). Results: Median follow up time was 3.6 years for the WLL/WLR and 3.0 years for AF. A score of &gt;1.5 SD from predicted on at least 2 of the 3 cognitive domains at the most recently administered test identified 543 cases. Further restriction to &gt;1.6 SD identified 497 cases. Most (85.5%) cases were impaired on WLL and WLR only; 14.5% of cases had impairment on AF ( Figure 1 ). By design, age, sex, race, and education did not differ between cases and non-cases. Residence in the stroke belt region, lower income, diabetes, heart disease, current smoking, alcohol abstinence, lack of weekly exercise, higher body mass index, and higher C-reactive protein were associated with case status. Conclusion: Defining cognitive decline based on deviation from age-, race-, sex-, and education- predicted scores on at least 2 cognitive domains identified a case phenotype that was associated with other demographic and adverse vascular risk factors.
THE MEDICAL LIBRARY AGAIN.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pasteur's Mistakes.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Evaluation of the economic impact of the CCP assay in localized prostate cancer.
Authors: E. David Crawford, Doria Cole, Nicolas Lewine, Gary Gustavsen
Journal: Journal of Clinical Oncology (2015)

e16037 Background: Stratification of localized prostate cancer based on disease aggressiveness remains challenging, resulting in overtreatment of low−risk patients and under treatment of high−risk patients. A biopsy−based, cell cycle progression (CCP) gene expression assay can aid physicians in predicting prostate cancer aggressiveness, leading to more appropriate patient management. This study quantifies the economic impact of the CCP assay on a US commercial health plan. Methods: A fact−based economic model was developed for a hypothetical cohort of prostate cancer patients with localized disease. Patients were followed in the model for 10 years with management and progression assumptions based on published clinical data and interviews with board−certified physicians. Total cost of care was calculated for a reference scenario (current clinical practice) and a test scenario where patient management was altered based on CCP test results. Cost inputs were set for each unit of care that a patient might undergo (diagnostic/surgical/radiotherapy procedures and pharmacological therapy); costs were assigned based on published costs of care. Total cost of care was compared between the two scenarios to determine overall system economic impact. Results: The CCP test reduced costs by $2,850/patient tested over 10 years after accounting for test cost. For a health plan with 10 million members, this would translate to over $16 million in savings with two−thirds of those savings achieved in the first year after testing. The majority of savings came from increased use of active surveillance in AUA low− and intermediate−risk patients. No single model input, when changed within a range of values, caused the model to show that the test was no longer cost saving. Costs of the test scenario were never greater than the reference scenario, resulting in cost savings over the 10 years modeled. Conclusions: Use of the CCP test in a US commercial health plan has the potential to result in cost savings to payers. Savings are due to increased use of active surveillance in low− and intermediate−risk patients with less aggressive disease, but also from reduced progression rates in high−risk patients with more aggressive disease who transition to multi−modality therapy.
Highlights
Journal: JAMA (2019)

Vasodilation for Acute Heart Failure 2292It is unclear whether early, aggressive vasodilation is benefi cial for most patients with acute heart failure (AHF).Kozhuharov and colleagues for the GALACTIC Investigators randomized 788 patients with AHF and found that a strategy of early intensive and sustained vasodilation, compared with usual care, did not signifi cantly improve a composite outcome of all-cause mortality and AHF rehospitalization at 180 days.In an Editorial, Curfman discusses the clinical management of acute decompensated heart failure with and without systemic hypertension.